Document is current

Article History

Received: 9 December 2024

Accepted: 16 April 2025

First Online: 22 May 2025

Declarations

:

: Daniel Teschner has received research grants from Gilead, honoraria from and served as a consultant to AbbVie, BioNTech, Gilead, iQone, Jazz, Mikrogen, MSD, Noscendo, Octapharma, Pfizer, Tillotts, and Takeda, honoraria from AstraZeneca, F2G, Janssen, Novartis, and Sanofi, and travel grants from AbbVie, Astellas, Celgene, Gilead, Jazz, Medac, MSD, and Tillotts. Jana Knop and Christian Piehl are employees of Takeda Pharma Vertrieb GmbH & Co. KG. Christian Piehl holds Takeda stocks. Tino Schubert is owner and employee of LinkCare GmbH, which received consulting honoraria from Takeda Pharma Vertrieb GmbH and Mallinckrodt Pharmaceuticals. Oliver Witzke received research grants for clinical studies, speaker’s fees, honoraria, and travel expenses from Alexion, Amgen, Astellas, Basilea, Biotest, Bristol Myers Squibb, Chiesi, Correvio, Gilead, Hexal, Janssen, Dr. F. Köhler Chemie, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda, Teva, and UCB, as well as an unrestricted grant from the Rudolf-Ackermann-Stiftung (Stiftung für Klinische Infektiologie).

: Participants were fully informed about the study’s objectives and the intent to publish the results. Consent was given voluntarily through signed contracts. Participant answers were anonymized, and no communication occurred between them during the study. Data protection adhered to GDPR regulations, with analyses conducted pseudonymously to ensure privacy. Ethical committee consultation was unnecessary as the study only involved physician responses, with no patient information and no interference with personal integrity.